好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Phase 2 Data Suggest Heterogeneity of Presentation and Comorbidity Burden Do Not Impact Activity of SAGE-547 in Patients with Super-Refractory Status Epilepticus
Epilepsy/Clinical Neurophysiology (EEG)
(-)
210
Authors/Disclosures
Helen Colquhoun
PRESENTER 		Helen Colquhoun has received personal compensation for serving as an employee of Sage Therapeutics. Helen Colquhoun has stock in Sage Therapeutics. Helen Colquhoun has received intellectual property interests from a discovery or technology relating to health care.
Mollie Baird No disclosure on file
Shane Raines Shane Raines has received personal compensation for serving as an employee of 2b Analytics, LLC.
No disclosure on file
Steve Kanes, MD, PhD (Sage Therapeutics) Dr. Kanes has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Kanes has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Verge Genomics. Dr. Kanes has received intellectual property interests from a discovery or technology relating to health care.